Applicant: Wei-Yu Lo et al. Attorney's Docket No.: 12875-002001 / 0643-5299US

Serial No. : 09/778,516
Filed : February 7, 2001

Page : 7 of 9

REMARKS

This document is filed in reply to the office action dated July 22, 2004 ("Office Action"). Applicants have amended claims 2-6 to promote clarity and to correct informalities. No new matter has been introduced.

Claims 1-16 are pending and under examination. Reconsideration of this application is requested in view of the following remarks:

Objection to the Specification

The Examiner objected to the Specification, contending that "[t]he specification contains sequence disclosures that are not identified by SEQ ID NO[s] (e.g., page 14, lines 24-25 and page 15, lines 16-17)." See the Office Action, page 3, second paragraph.

Applicants disagree. The two passages of the Specification at issue disclose four PCR primers, i.e., (i) aagetcatga ttggcageca gtctccgggc; (ii) gacctcatga accgtcgcta gcgacacgcc; (iii) ttaacgatcg ttagaagcaa acttaagagt g; and (iv) ttaacgatcg atgtaatcac tccttct. They, as well as other sequences disclosed in the Specification, are identified by SEQ ID NOs. See the sequence listing submitted with Applicants' response mailed April 22, 2002. For this reason, Applicants request that the objection be withdrawn.

Objection to claims 2 and 4-6

The Examiner objected to claims 2 and 4-6 for containing informalities. Applicants have corrected the informalities, and submit that the objection has been overcome.

Rejection under 35 U.S.C. § 112, second paragraph

The Examiner rejected claim 3 as being indefinite. See the Office Action, page 5, last paragraph. Applicants have amended this claim in the manner suggested by the Examiner, thereby overcoming the rejection.

Attorney's Docket No.: 12875-002001 / 0643-5299US

Applicant: Wei-Yu Lo et al. Serial No.: 09/778,516 Filed: February 7, 2001

Page : 8 of 9

Rejection under 35 U.S.C. § 112, first paragraph

The Examiner rejected claim 13, 15, and 16 under § 112, first paragraph on two grounds. Applicants traverse each below:

Ι

Claim 13, drawn to a DNA immunogenic composition, was rejected for lack of enablement. More specifically, it is the Examiner's position that he "can find no asserted use for an immunogenic composition according to the claims other than as a vaccine ... the disclosure fails to provide enablement for the broad scope of immunogenic composition comprising an antigenic gene, wherein said immunogenic compositions are useful as vaccines" See the Office Action, page 3, first paragraph.

Applicants disagree. Indeed, the Specification clearly teaches a number of uses of the claimed composition. For example, the composition, which contains a Lac shuttle vector, allows one "to express a heterologous gene in an organism or as a DNA vaccine or health food." See, e.g., the Specification, page 2, lines 11-15; and page 24, lines 15-18. In other words, the claimed composition has utilities other than vaccination. Further, the Specification provides sufficient teachings as to how to make and use the claimed composition. Thus, claim 13 meets the enablement requirement.

II

Claims 15 and 16, covering a Lac shuttle vector and a composition containing the vector, were rejected for containing new matter. The vector includes a nucleic acid encoding "a protein consisting essentially of the sequence of the Rep A protein." According to the Examiner, "the originally filed application and claims do not disclose a sequence for the Rep A protein." See the Office Action, page 5, second paragraph.

Applicants disagree and note that the Specification teaches such a sequence, e.g., a "Rep A protein ... of 317 amino acids." See, e.g., page 7, lines 21-28 of the Specification. In addition, as acknowledged by the Examiner, the just-quoted passage cites several references (e.g., Bouia et al, 1989, Plasmid, 22: 185-192), which disclose nucleic acids encoding the Rep A protein. See, the Office Action, page 2, lines 18-20.

Applicant: Wei-Yu Lo et al. Attorney's Docket No.: 12875-002001 / 0643-5299US

Serial No. : 09/778,516 Filed : February 7, 2001

Page: 9 of 9

In particular, Bouia et al., as well as the corresponding GenBank record, discloses the above-mentioned 317-amino acid Rep A protein and the encoding nucleotide sequence. See GenBank M31223 (copy attached hereto as "Exhibit A."). As shown in this exhibit, nucleotide (nt) 262-1215 of GenBank M31223 encodes the Rep A protein. In this connection, Applicants would point out that the Specification discloses the same nucleotide sequence, i.e., nt 3198-4151 of SEQ ID NO: 1 (i.e., FIGs. 5A-G) as originally filed. For the reasons set forth above, the Examiner clearly erred in asserting that "the originally filed application and claims do not disclose a sequence for the Rep A protein." To promote clarity, Applicants have amended the Specification to identify the amino acid sequence (SEQ ID NO: 8) and the nucleotide sequence (SEQ ID NO: 7) of the Rep A protein and submitted a copy of a substitute sequence listing.

CONCLUSION

Applicants submit that the rejections asserted by the Examiner have been overcome, and that the claims, as amended, define subject matter that is definite and sufficiently described.

Allowance of this application is therefore proper, and early favorable action is solicited.

Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: 9-22-04

Y/Rocky Tsa

Altorney for Applicant

Reg. No. 34,053

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 Telephone: (617) 542-5070

Facsimile: (617) 542-8906

20933202.doc

Books

Links

Details

Features



NCBI Sequence Viewer

//

```
/note="direct repeat E"
                     1420...1436
     <u>repeat region</u>
                     /note="direct repeat F"
                     1437...1453
     repeat_region
                     /note="direct repeat G"
     repeat region
                     1456. . 1467
                     /note="direct repeat H"
                     1468...1484
     repeat region
                     /note="direct repeat I"
                     1485...1501
     repeat_region
                     /note="direct repeat J"
                     1504..1520
     <u>repeat_region</u>
                     /note="direct repeat K"
     repeat region
                     1521...1537
                     /note="direct repeat L"
                     1538. . 1554
     repeat_region
                     /note="direct repeat M"
                     2051..2064
     rep_origin
                     /note="origin of replication (put.); putative"
ORIGIN
            1 bp upstream of HindIII site.
        1 aagcttgatt aggcttaatt gggcttgtat ccattgattt tataggcttt tggtgtatta
       61 ttagggttat aaattggttg aaagaaagac aaaataaaaa cccacgtgca aattcctagt
      121 ttggccgctc ggaacacgtg agttgattat catttgcgat ttatagccta ttctagggga
      181 aaageeetat gatgteaagg ttataagett attgaaaaag atagteaget eetteacgte
241 gataaactgg aggagetttt tatgteagaa atttttgaag ataaaactga aaatggeaaa (nt 262-1215
      301 gttagacctt ggcgagaacg gaagattgaa aatgtgcgct atgccgaata tttggcaatc
      361 ttagaattta aacgggcaca tgatgtacgg ggttgtggtg aagttttgcg ttttcgtaag
      421 attggcgagc acttaaaact ttatcaaacg tggttttgtc ataaacgatt gtgtccattg
      481 tgtaattgga gaaggagcat gaaaaactcg agccagttaa aacaaattat tgcggaagca
      541 gttgcaagag agcctaaagg acggtttttg tttttaactt taaccgttaa aaacgctcat
      601 tcagcagagg agttaaaagt gtctttaaga gctttgacta aagcctttaa taagctaact
      661 cgctataaaa aagtgactaa aaatttattg ggttatttac gttcaacgga aattaccgtt
      721 aatgaacaag acgggtcata taatcaacac ttgcatgtgt tgctgtttgt aaaatcaagt
      781 tattttaaga attcaaataa ttatttagca caagcagaat gggcaaaatt atggcaaaaa
         gccttgaaag ttgattatga gcctgtggtg catgtgcagg ctgttaaagc taacaaacgt
      901 aaaggaactg actotttgca agotagtgco gaagaaacgg cgaaatacga ggtaaaatca
      961 gctgattata tgacggctga tgatgagcgt aatttggtgg tgattaaaaa tttggagtat
     1021 gccttagctg gaacacgaca aatcagctat ggtggattat taaagcaaat taagcaagat
     1081 ttgaaacttg aagatgttga gaatggtgat ttagttcatg ttggcgatga agattacacc
     1141 aaagagcaaa tggaagctgc ggaagaagtt gtcgcaaaat gggattttaa taaacaaaat
     1201 tattttattt ggtaaagaa atgtcaggat atgatcaacg gtaaatccgt tggcatatcc
     1261 ctttttigtt gtcagcttgc tgacttctga tacaggtttt agcattactc caatttattt
     1321 ggagtgtaag tgcacattat catgtagtgc gcattatcat gtagtgcgca ttatcatgta
     1381 gtgcgcatta tcatgtagtg cgcattatca tgtagtgcgc attatcatgt agtgcgcatt
     1441 atcatgtagt gcgcacatta tcatgtacat tatcatgtag tgcgcattat catgtagtgc
     1501 gcacattatc atgtagtgcg cattatcatg tagtgcgcat tatcatgtag tgcgcactta
     1561 cacacaacat gaagttgtgt tgtgctaaac ccatcaaaac ctgcatcaga tttcgcgttg
     1621 ctcaaacgta actgacttgc gtcagtttgg aacattcaaa aataaataag ttcagtcgct
     1681 ageteetteg aacttttta tttttgaacg ttaattttaa aggetettat ttgegtteta
     1741 agcgatttta gctaacagtt agctatctaa ctgtctgtca acggtaaatc gacttagagg
     1801 ggcttattga gccttacagg cgatattagc ccctcttgga ggctttaagg agttgataga
     1861 ctagacaata ccaaaagcct gacgtcttgg aaaacaagcc cttgttttcc cgagcccagc
     1921 ggcggcaagc gttacggtcc agctggttca gctggtcagt gtggctgaaa gccacggttt
     1981 aaaaaaagca gttcagcggt ttttgctgat ctgctttttg gggtttaaaa acgcaatttt
     2041 tggcgttttc ttcttatctt gatactatta gcaacaacta gttttttaaa atc
```

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

Aug 30 2004 07:13:44